DK2343038T3 - Dermatologiske sammensætninger indeholdende en kombination af peroxiderede lipider og zink samt deres anvendelse, især til behandling af herpes - Google Patents
Dermatologiske sammensætninger indeholdende en kombination af peroxiderede lipider og zink samt deres anvendelse, især til behandling af herpes Download PDFInfo
- Publication number
- DK2343038T3 DK2343038T3 DK10195981.5T DK10195981T DK2343038T3 DK 2343038 T3 DK2343038 T3 DK 2343038T3 DK 10195981 T DK10195981 T DK 10195981T DK 2343038 T3 DK2343038 T3 DK 2343038T3
- Authority
- DK
- Denmark
- Prior art keywords
- composition
- composition according
- herpes
- oil
- zinc oxide
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 120
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 title claims description 59
- 150000002632 lipids Chemical class 0.000 title claims description 49
- 238000011282 treatment Methods 0.000 title claims description 38
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title claims description 10
- 239000011701 zinc Substances 0.000 title claims description 10
- 229910052725 zinc Inorganic materials 0.000 title claims description 10
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 79
- 239000011787 zinc oxide Substances 0.000 claims description 40
- 210000003491 skin Anatomy 0.000 claims description 36
- 210000004400 mucous membrane Anatomy 0.000 claims description 31
- 208000024891 symptom Diseases 0.000 claims description 30
- 208000003251 Pruritus Diseases 0.000 claims description 26
- 208000001688 Herpes Genitalis Diseases 0.000 claims description 23
- 201000004946 genital herpes Diseases 0.000 claims description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 22
- 239000006071 cream Substances 0.000 claims description 18
- 230000007803 itching Effects 0.000 claims description 17
- 239000003921 oil Substances 0.000 claims description 17
- 235000019198 oils Nutrition 0.000 claims description 17
- 230000000699 topical effect Effects 0.000 claims description 15
- 206010039509 Scab Diseases 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 238000005502 peroxidation Methods 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 11
- 230000003628 erosive effect Effects 0.000 claims description 11
- 206010015150 Erythema Diseases 0.000 claims description 10
- 206010030113 Oedema Diseases 0.000 claims description 10
- 231100000321 erythema Toxicity 0.000 claims description 10
- 230000003902 lesion Effects 0.000 claims description 10
- 210000002615 epidermis Anatomy 0.000 claims description 9
- 239000003755 preservative agent Substances 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 239000003205 fragrance Substances 0.000 claims description 8
- 230000008929 regeneration Effects 0.000 claims description 8
- 238000011069 regeneration method Methods 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 7
- 239000008119 colloidal silica Substances 0.000 claims description 7
- 235000005687 corn oil Nutrition 0.000 claims description 6
- 238000001959 radiotherapy Methods 0.000 claims description 6
- 235000019485 Safflower oil Nutrition 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000002285 corn oil Substances 0.000 claims description 5
- 239000003813 safflower oil Substances 0.000 claims description 5
- 235000005713 safflower oil Nutrition 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- 239000003349 gelling agent Substances 0.000 claims description 4
- 244000144725 Amygdalus communis Species 0.000 claims description 3
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 3
- 235000019483 Peanut oil Nutrition 0.000 claims description 3
- 239000008168 almond oil Substances 0.000 claims description 3
- 239000003925 fat Substances 0.000 claims description 3
- 239000000312 peanut oil Substances 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- 235000019487 Hazelnut oil Nutrition 0.000 claims description 2
- 206010042496 Sunburn Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 230000000202 analgesic effect Effects 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 239000008169 grapeseed oil Substances 0.000 claims description 2
- 239000010468 hazelnut oil Substances 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 239000008159 sesame oil Substances 0.000 claims description 2
- 235000011803 sesame oil Nutrition 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 208000035824 paresthesia Diseases 0.000 claims 1
- 239000002304 perfume Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 210000004927 skin cell Anatomy 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 33
- 239000000902 placebo Substances 0.000 description 30
- 229940068196 placebo Drugs 0.000 description 30
- 229940107931 zovirax Drugs 0.000 description 26
- 239000013641 positive control Substances 0.000 description 18
- 239000000499 gel Substances 0.000 description 16
- 239000003814 drug Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 208000025865 Ulcer Diseases 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 230000035876 healing Effects 0.000 description 10
- 206010033733 Papule Diseases 0.000 description 9
- 230000000840 anti-viral effect Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000036269 ulceration Effects 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 8
- 150000003752 zinc compounds Chemical class 0.000 description 8
- 229960004150 aciclovir Drugs 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229910002018 Aerosil® 300 Inorganic materials 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 239000000730 antalgic agent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- -1 edema Chemical compound 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000004392 genitalia Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 4
- 210000001217 buttock Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 238000006748 scratching Methods 0.000 description 3
- 230000002393 scratching effect Effects 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 3
- 229960001763 zinc sulfate Drugs 0.000 description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 238000013475 authorization Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 210000000609 ganglia Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000003905 vulva Anatomy 0.000 description 2
- 239000010457 zeolite Substances 0.000 description 2
- QYYMDNHUJFIDDQ-UHFFFAOYSA-N 5-chloro-2-methyl-1,2-thiazol-3-one;2-methyl-1,2-thiazol-3-one Chemical compound CN1SC=CC1=O.CN1SC(Cl)=CC1=O QYYMDNHUJFIDDQ-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 206010004078 Balanoposthitis Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000001299 hyperoxygenation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910002055 micronized silica Inorganic materials 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- PFUVRDFDKPNGAV-UHFFFAOYSA-N sodium peroxide Chemical compound [Na+].[Na+].[O-][O-] PFUVRDFDKPNGAV-UHFFFAOYSA-N 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000021081 unsaturated fats Nutrition 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (20)
1. Dermatologisk og/eller farmaceutisk sammensætning, kendetegnet ved, at den som essentielle aktive stoffer indeholder en kombination af peroxiderede lipider og zink i form af en med dermatologisk anvendelse forenelig forbindelse dannet af zinkoxid, idet sammensætningen er formuleret til topisk anvendelse på huden eller slimhinderne.
2. Sammensætning ifølge krav 1, kendetegnet ved, at de peroxiderede lipider har en peroxidationsgrad mellem 5 og 600 milliækvivalenter pr. kg peroxiderede lipider.
3. Sammensætning ifølge krav 1 eller 2, kendetegnet ved, at de peroxiderede lipider har en peroxidationsgrad mellem 30 og 500 milliækvivalenter pr. kg, fortrinsvis mellem 50 og 300 milliækvivalenter pr. kg og endnu mere foretrukket mellem 50 og 150 milliækvivalenter pr. kg peroxiderede lipider.
4. Sammensætning ifølge et af kravene 1 til 3, kendetegnet ved, at de peroxiderede lipider som aktive stoffer eller hovedbestanddele i forhold til summen af aktive stoffer omfatter delvis oxiderede triglycerider med den almene formel:
i hvilken grupperne R er delvis peroxiderede umættede C18-syrer.
5. Sammensætning ifølge et af kravene 1 til 4, kendetegnet ved, at de peroxiderede lipider er opnået ved peroxidation af lipider eller fedtstoffer af naturlig oprindelse, fortrinsvis lipider fra en naturlig vegetabilsk olie.
6. Sammensætning ifølge krav 5, kendetegnet ved, at den naturlige olie er valgt fra gruppen, der består af sødmandelolie, hasselnøddeolie, jordnøddeolie, majsolie, druekerneolie, sesamolie og safflorolie og blandinger deraf.
7. Sammensætning ifølge et af kravene 1 til 6, kendetegnet ved, at zinkoxidet foreligger i mikroniseret form.
8. Sammensætning ifølge et af kravene 1 til 7, kendetegnet ved, at den indeholder fra 0,1 til 25 vægt% zinkoxid.
9. Sammensætning ifølge et af kravene 1 til 8, kendetegnet ved, at den indeholder fra 1 til 25% zinkoxid.
10. Sammensætning ifølge et af kravene 1 til 9, kendetegnet ved, at den foreligger i form af en olieagtig gel eller en creme.
11. Sammensætning ifølge krav 10, kendetegnet ved, at den olieagtige gel består af peroxiderede lipider, zinkoxid, et geleringsmiddel, især kolloidt silica og eventuelt konserveringsmidler og/eller parfume eller duftstof og/eller formuleringshjælpestoffer, der er beregnede til at forbedre de galeniske egenskaber eller lette påføringen af sammensætningen.
12. Sammensætning ifølge et af kravene 1 til 11, kendetegnet ved, at den foreligger i form af en gel, der omfatter en kombination i vægtprocent: peroxiderede lipider fra 50 til 99%, mikroniseret zinkoxid fra 1,0 til 25%.
13. Sammensætning ifølge et af kravene 1 til 12, kendetegnet ved, at den foreligger i form af en gel, der i relative vægtprocent omfatter: - peroxiderede lipider fra 50 til 95%; - zinkoxid fra 1,0 til 25%; - et geleringsmiddel omfattende siliciumdioxid fra 1 til 10,0%; eventuelt konserveringsmiddel 0,1 til 1,0; - eventuelt duftstoffer 0,5 til 5%.
14. Sammensætning ifølge et af kravene 1 til 10, kendetegnet ved, at den foreligger i form af en creme, der er fremstillet ud fra en emulsion, især en olie-i-vand-emulsion, idet emulsionens oliefase er dannet af de peroxiderede lipider, der udgør fra 1 til 25 vægt% af sammensætningen.
15. Medicinsk indretning, kendetegnet ved, at den er dannet af en sammensætning ifølge et af kravene 1 til 14.
16. Anvendelse af en sammensætning ifølge krav 1 til 14 som medicinsk indretning ifølge krav 15 til at fremme sårheling eller regenerering af huden eller slimhinderne og/eller fornyelse af hudcellerne og således bidrage til genopretning af skadet epidermis og/eller tjene som analgetisk middel på huden eller slimhinderne.
17. Anvendelse ifølge krav 16, kendetegnet ved, at sammensætningen som medicinsk indretning er beregnet til behandling af symptomer på herpes: smerte, brænden, pruritus, prikken, ødem, sår/erosioner, erythem, blegner, småblærer eller skorper.
18. Anvendelse ifølge krav 16, kendetegnet ved, at sammensætningen som medicinsk indretning er beregnet til behandling af symptomer på forbrændinger, efter stråleterapi eller fremkaldt af behandlinger af hudkræft eller forstadier for hudkræft, eller enhver anden forbrænding, især solskoldning.
19. Anvendelse ifølge krav 16, kendetegnet ved, at sammensætningen som medicinsk indretning er beregnet til behandling af symptomer på kronisk pruritus sine materia, kløe og kradsningslæsioner.
20. Anvendelse ifølge krav 16 eller 17, kendetegnet ved, at sammensætningen som medicinsk indretning er beregnet til behandling af læbe- eller genitalherpes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0959604A FR2954701B1 (fr) | 2009-12-24 | 2009-12-24 | Compositions dermatologiques contenant une association de lipides peroxydes et de zinc et leurs utilisations notamment dans le traitement de l'herpes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2343038T3 true DK2343038T3 (da) | 2015-01-26 |
Family
ID=42227561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10195981.5T DK2343038T3 (da) | 2009-12-24 | 2010-12-20 | Dermatologiske sammensætninger indeholdende en kombination af peroxiderede lipider og zink samt deres anvendelse, især til behandling af herpes |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9144612B2 (da) |
| EP (1) | EP2343038B1 (da) |
| AR (1) | AR080633A1 (da) |
| BR (1) | BRPI1010325B1 (da) |
| CY (1) | CY1115914T1 (da) |
| DK (1) | DK2343038T3 (da) |
| ES (1) | ES2531407T3 (da) |
| FR (1) | FR2954701B1 (da) |
| HR (1) | HRP20150027T1 (da) |
| PL (1) | PL2343038T3 (da) |
| PT (1) | PT2343038E (da) |
| RS (1) | RS53787B1 (da) |
| SI (1) | SI2343038T1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012136218A1 (en) * | 2011-04-04 | 2012-10-11 | Coloplast A/S | An adhesive patch |
| ES2856553T3 (es) * | 2015-03-18 | 2021-09-27 | Bionoox Suisse Sa | Composiciones que comprenden dihidroquercetina para uso en métodos para el tratamiento del herpes |
| KR20170139143A (ko) * | 2015-06-12 | 2017-12-18 | 제이에프이미네라르 가부시키가이샤 | 피부 창상 또는 피부 거침 치료제 |
| FR3053252B1 (fr) * | 2016-06-29 | 2020-04-24 | Laboratoires Carilene | Produit, ou agent actif, ou composition pour le soin des seins en periode pre-mensuelle ou menstruelle ou pour le soin de la symptomatologie des mastodynies |
| WO2025230397A1 (fr) * | 2024-04-29 | 2025-11-06 | Az-Pharma Laboratoires | Formulation dermatologique sans alcool pour l'acné, l'herpès et les plaies superficielles |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2461744A1 (fr) * | 1979-07-19 | 1981-02-06 | Desjonqueres Stephane | Perfectionnement a la peroxydation de matieres grasses |
| FR2591109B1 (fr) | 1985-12-06 | 1989-03-31 | Desjonqueres Stephane | Composition medicamenteuse a base d'huile naturelle d'origine vegetale destinee a etre utilisee pour le traitement d'herpes. |
| JPH06698B2 (ja) * | 1985-12-26 | 1994-01-05 | 積水化学工業株式会社 | 外用貼付剤 |
| FR2731615B1 (fr) * | 1995-03-15 | 1997-07-25 | Fabre Pierre Dermo Cosmetique | Compositions ecran-solaire comprenant un melange de particules d'oxyde de titane et/ou de zinc, leur procede de preparation et leur utilisation |
| FR2744017B1 (fr) * | 1996-01-26 | 1998-04-30 | Carilene Lab | Associations de lipides peroxydes et de composes organosiliciques, compositions cosmetiques et dermatologiques les contenant et leurs applications notamment pour le traitement de l'alopecie |
| FR2797586B1 (fr) * | 1999-08-16 | 2001-11-09 | Stephane Desjonqueres | Utilisation de lipides peroxydes comme agents destines a former un film lipidique sur la peau |
| FR2824474B1 (fr) * | 2001-05-11 | 2004-01-02 | Fabre Pierre Dermo Cosmetique | Composition cosmetique a base de sucralfate et de sulfates de cuivre et de zinc |
| US6475526B1 (en) * | 2001-06-05 | 2002-11-05 | Jeffrey B. Smith | Zinc containing compositions for anti-viral use |
| DE10161729A1 (de) * | 2001-12-15 | 2003-06-18 | Mira Ursic | Medizinische bzw. pharmazeutische Salbenzubereitung |
| US6686392B1 (en) * | 2002-10-01 | 2004-02-03 | Elena Avram | Lipidic zinc compounds and use for treatment of prostatic hypertrophy |
| NL1022532C2 (nl) * | 2003-01-30 | 2004-08-03 | Pronovamedical B V | Samenstelling voor de preventieve behandeling van koortsuitslag. |
| CA2514381A1 (en) * | 2005-07-29 | 2007-01-29 | Collins T. Harvey | Improved topical preparation and method for using same to destroy herpes simplex cells |
| ITRM20070582A1 (it) * | 2007-11-08 | 2009-05-09 | Mauro Carratelli | Composizione farmaceutica comprendente olio e colesterolo perossidati e suoi usi in campo medico. |
-
2009
- 2009-12-24 FR FR0959604A patent/FR2954701B1/fr active Active
-
2010
- 2010-12-17 US US12/971,055 patent/US9144612B2/en active Active
- 2010-12-20 DK DK10195981.5T patent/DK2343038T3/da active
- 2010-12-20 ES ES10195981T patent/ES2531407T3/es active Active
- 2010-12-20 RS RS20150043A patent/RS53787B1/sr unknown
- 2010-12-20 EP EP10195981.5A patent/EP2343038B1/fr active Active
- 2010-12-20 SI SI201030868T patent/SI2343038T1/sl unknown
- 2010-12-20 BR BRPI1010325A patent/BRPI1010325B1/pt not_active IP Right Cessation
- 2010-12-20 PL PL10195981T patent/PL2343038T3/pl unknown
- 2010-12-20 PT PT101959815T patent/PT2343038E/pt unknown
- 2010-12-22 AR ARP100104870A patent/AR080633A1/es not_active Application Discontinuation
-
2014
- 2014-12-29 CY CY20141101089T patent/CY1115914T1/el unknown
-
2015
- 2015-01-09 HR HRP20150027AT patent/HRP20150027T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20150027T1 (hr) | 2015-03-13 |
| BRPI1010325A2 (pt) | 2014-02-25 |
| FR2954701A1 (fr) | 2011-07-01 |
| PT2343038E (pt) | 2015-02-05 |
| BRPI1010325B1 (pt) | 2019-09-03 |
| EP2343038A1 (fr) | 2011-07-13 |
| US9144612B2 (en) | 2015-09-29 |
| PL2343038T3 (pl) | 2015-04-30 |
| AR080633A1 (es) | 2012-04-25 |
| FR2954701B1 (fr) | 2012-02-03 |
| ES2531407T3 (es) | 2015-03-13 |
| US20110159106A1 (en) | 2011-06-30 |
| EP2343038B1 (fr) | 2014-11-26 |
| SI2343038T1 (sl) | 2015-03-31 |
| CY1115914T1 (el) | 2017-01-25 |
| RS53787B1 (sr) | 2015-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7559173B2 (ja) | 皮膚炎および炎症性皮膚状態のためのカンナビノイド投薬レジメン | |
| TWI243676B (en) | Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors | |
| JP2025109935A (ja) | カンナビジオールを含む局所製剤、組成物の調整方法およびその方法 | |
| CA2453823C (en) | Dermal therapy using phosphate derivatives of electron transfer agents | |
| US20130108599A1 (en) | Herbal Vaginal Compositions | |
| DK2343038T3 (da) | Dermatologiske sammensætninger indeholdende en kombination af peroxiderede lipider og zink samt deres anvendelse, især til behandling af herpes | |
| US20220110993A1 (en) | Compositions for treatment of jaw pain, temporomandibular joint and muscle disorder and bruxism | |
| RU2496476C1 (ru) | Средство наружной терапии для больных атопическим дерматитом | |
| ES2379474T3 (es) | Producto dermatológico para el tratamiento y/o cuidado de la piel con neurodermitis | |
| US11351146B2 (en) | Topical compositions for the treatment of cutaneous leishmaniasis | |
| ITUB20159582A1 (it) | Composizione, per uso topico, utile per la prevenzione di disturbi di tipo infiammatorio e/o infettivo delle mucose. | |
| US20050013821A1 (en) | Mint extract and related pharmaceutical compositions | |
| Lewis | Topical and Non‐Surgical Treatments | |
| JP2016518424A (ja) | ヘルペス処置のための薬剤と方法 | |
| EP3506876A1 (en) | Composition for nail fungus | |
| JP2018507895A (ja) | ヘルペスを処置するための方法において使用するためのジヒドロケルセチンを含む組成物 | |
| CN106491512A (zh) | 一种生物蛋白酶新生精华霜 | |
| CN120899927A (zh) | 促进局部组织一氧化氮释放水平增加的组合物及其用途 | |
| BR102023017423A2 (pt) | Composições emolientes para cuidados com a pele e cutículas | |
| KR20220098938A (ko) | 희토류 복합바이오광물질의 증류추출액을 활성성분으로 함유하는 피부외용제 조성물 | |
| JP2013542208A (ja) | 皮膚の治療用組成物 | |
| CN110996939A (zh) | 用于治疗皮肤利什曼病的方法的组合物 | |
| MXPA01000368A (en) | Vitamin e and esters thereof for use in the topical treatment of mucosal pathologies | |
| PL205047B1 (pl) | Zastosowanie dinukleotydu nikotynamido-adeninowego (NAD) i/lub fosforanu dinukleotydu nikotynamido-adeninowego (NADP) do leczenia łuszczycy |